Essex Investment Management Co. LLC Has $326,000 Stock Position in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)

Essex Investment Management Co. LLC lessened its stake in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) by 10.3% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 24,442 shares of the company’s stock after selling 2,810 shares during the quarter. Essex Investment Management Co. LLC’s holdings in Eton Pharmaceuticals were worth $326,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Connor Clark & Lunn Investment Management Ltd. grew its position in Eton Pharmaceuticals by 86.6% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,014 shares of the company’s stock worth $390,000 after acquiring an additional 30,167 shares during the last quarter. Wasatch Advisors LP acquired a new stake in shares of Eton Pharmaceuticals during the third quarter valued at about $1,431,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Eton Pharmaceuticals during the third quarter worth about $54,000. Parkman Healthcare Partners LLC grew its holdings in shares of Eton Pharmaceuticals by 2.8% during the third quarter. Parkman Healthcare Partners LLC now owns 260,226 shares of the company’s stock worth $1,561,000 after purchasing an additional 7,029 shares during the last quarter. Finally, Jane Street Group LLC acquired a new position in shares of Eton Pharmaceuticals in the third quarter valued at approximately $90,000. 27.86% of the stock is currently owned by institutional investors and hedge funds.

Eton Pharmaceuticals Price Performance

Shares of ETON stock opened at $14.59 on Monday. The stock has a market capitalization of $380.08 million, a PE ratio of -66.32 and a beta of 1.37. The business’s 50 day simple moving average is $15.22 and its 200 day simple moving average is $10.92. Eton Pharmaceuticals, Inc. has a one year low of $3.03 and a one year high of $18.41.

Wall Street Analysts Forecast Growth

ETON has been the topic of a number of research reports. Craig Hallum boosted their target price on shares of Eton Pharmaceuticals from $15.00 to $18.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. HC Wainwright lifted their price target on shares of Eton Pharmaceuticals from $17.00 to $33.00 and gave the stock a “buy” rating in a report on Thursday, January 23rd. Finally, B. Riley assumed coverage on Eton Pharmaceuticals in a report on Friday, January 10th. They issued a “buy” rating and a $21.00 price objective for the company.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.